Abstract

Adrenal gland tumors are growths that develop in the small, triangular glands located atop each kidney. These tumors can be functional (producing excess hormones) or non-functional, and benign (adenomas) or malignant (carcinomas). This article explores the pathophysiology, clinical presentation, and multifaceted management strategies required to treat these conditions.

Keywords: Adrenal Adenoma, Pheochromocytoma, Cortisol, Adrenocortical Carcinoma, Endocrinology, Hormone Hypersecretion.

Introduction

The adrenal glands are vital components of the endocrine system, consisting of an outer cortex and an inner medulla. They produce essential hormones like cortisol, aldosterone, and adrenaline. When cells in these glands mutate and grow uncontrollably, a tumor forms. While many adrenal masses are discovered incidentally (often called "incidentalomas"), some can cause life-threatening hormonal imbalances or systemic malignancy.

Types of Adrenal Tumors

Adrenal tumors are primarily categorized by their origin and whether they are cancerous:

1.     Adrenal Adenoma: The most common type; a benign tumor of the cortex.

2.     Adrenocortical Carcinoma (ACC): A rare but aggressive malignant tumor of the cortex.

3.     Pheochromocytoma: A tumor of the medulla that produces excess catecholamines (adrenaline).

4.     Neuroblastoma: A type of cancer that usually develops in the adrenal glands of children.

5.     Metastatic Tumors: Cancer that has spread to the adrenals from other organs (like the lungs or breast).

Pathology

The pathology of adrenal tumors depends on the zone of origin:

●       Zona Glomerulosa: Leads to excess Aldosterone (Conn’s Syndrome).

●       Zona Fasciculata: Leads to excess Cortisol (Cushing’s Syndrome).

●       Zona Reticularis: Leads to excess Androgens (Virilization).

●       Adrenal Medulla: Leads to excess Catecholamines (Hypertension/Tachycardia).

Signs and Symptoms

Symptoms vary based on whether the tumor is "functional" (secreting hormones):

●       Cushing’s Syndrome symptoms: Weight gain (moon face/buffalo hump), purple stretch marks, and high blood sugar.

●       Conn’s Syndrome symptoms: High blood pressure and low potassium (causing muscle weakness).

●       Pheochromocytoma symptoms: "The Classic Triad"—Headache, sweating, and rapid heart rate.

●       Malignancy signs: Unexplained weight loss and abdominal pain.

Risk Factors and Complications

Risk Factors:

●   Genetic syndromes (MEN2, Li-Fraumeni syndrome, von Hippel-Lindau disease).

●       Family history of endocrine tumors.

Complications:

●       Hypertensive Crisis: Specifically with pheochromocytomas.

●       Heart Failure: Due to chronic hormone exposure.

●       Metastasis: Spread of ACC to lungs or liver.

●       Osteoporosis: Caused by chronic cortisol excess.

Diagnosis and Lab Tests

Diagnosis requires a combination of biochemical testing and imaging.

Lab Tests:

●       24-Hour Urinary Free Cortisol: To check for Cushing's.

●       Plasma Metanephrines: Highly sensitive test for Pheochromocytoma.

●       Aldosterone-to-Renin Ratio (ARR): To screen for Conn’s syndrome.

●       Dexamethasone Suppression Test: To evaluate cortisol regulation.

Imaging:

●       CT Scan (Adrenal Protocol): Evaluates the "Hounsfield Units" (density) of the mass.

●       MRI: Useful for distinguishing between benign and malignant growths.

Treatment and Medication

Treatment is highly individualized based on tumor type and size.

Surgical Intervention

●       Adrenalectomy: The surgical removal of the adrenal gland. This is the gold standard for malignant or highly functional tumors.

Medication and Dosing

Note: Dosages must be managed by an oncologist or endocrinologist.

1.     For Cushing’s (Ketoconazole): 200 mg to 400 mg orally three times daily to inhibit steroid synthesis.

2.     For Pheochromocytoma (Phenoxybenzamine): Alpha-blocker used pre-operatively. Starting dose 10 mg twice daily, increased until blood pressure is controlled.

3.     For Advanced Carcinoma (Mitotane): 2 g to 6 g per day in divided doses. This is a potent adrenal-selective cytotoxic agent.

4.     Spironolactone: 25 mg to 100 mg daily for patients with aldosterone-secreting tumors to manage hypertension.

Discussion

The management of adrenal tumors has evolved significantly with the rise of laparoscopic surgery, which reduces recovery time. However, the "Incidentaloma" remains a clinical challenge. Doctors must balance the risk of unnecessary surgery for a benign "spot" against the risk of missing a subclinical functional tumor or an early-stage carcinoma.

Conclusion

Adrenal tumors represent a complex intersection of surgery and internal medicine. Early detection through hormonal screening and high-quality imaging is key to preventing the severe cardiovascular and metabolic complications associated with these growths. While most are benign, the potential for malignancy or "hormonal storms" necessitates vigilant medical follow-up.

References

1.     Fassnacht, M., et al. (2018). "Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline." European Journal of Endocrinology, Vol 175, pp. G1-G34. Link to EJE

2.     National Cancer Institute (NCI). (2023). "Adrenocortical Carcinoma Treatment (PDQ®)." NIH Health Documents, pp. 12-45. Link to NCI

3.     Young, W. F. (2021). "The Incidental Adrenal Mass." The New England Journal of Medicine, Vol 356, pp. 601-610. Link to NEJM